TCGA-BH-A0E9-01B-11R-A115-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 83
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.410
- UV_RESPONSE_DN+0.310
- HEDGEHOG_SIGNALING+0.220
- NOTCH_SIGNALING+0.220
- ESTROGEN_RESPONSE_EARLY+0.200
- APICAL_SURFACE+0.180
- APICAL_JUNCTION+0.140
- KRAS_SIGNALING_DN+0.120
- MYOGENESIS+0.110
- P53_PATHWAY+0.110
Top 10 suppressed
- MYC_TARGETS_V2-0.610
- E2F_TARGETS-0.550
- MYC_TARGETS_V1-0.520
- INTERFERON_ALPHA_RESPONSE-0.470
- MTORC1_SIGNALING-0.460
- G2M_CHECKPOINT-0.450
- DNA_REPAIR-0.430
- OXIDATIVE_PHOSPHORYLATION-0.380
- UNFOLDED_PROTEIN_RESPONSE-0.380
- INTERFERON_GAMMA_RESPONSE-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1313116 | — | A | 0.921 |
| 2 | SRR8613714 | — | A | 0.914 |
| 3 | TCGA-D8-A4Z1-01A-21R-A266-07 | — | A | 0.905 |
| 4 | TCGA-D8-A145-01A-11R-A115-07 | — | A | 0.889 |
| 5 | TCGA-A2-A1G6-01A-11R-A13Q-07 | — | A | 0.888 |
| 6 | TCGA-44-6148-01A-11R-1755-07 | — | cohortA1 | 0.886 |
| 7 | TCGA-AC-A2FK-01A-12R-A180-07 | — | A | 0.884 |
| 8 | s0122235 | — | — | 0.872 |
| 9 | TCGA-A7-A4SC-01A-12R-A266-07 | — | A | 0.867 |
| 10 | SRR10900546 | — | — | 0.863 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.410 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.310 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.220 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.220 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.180 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.140 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.120 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.110 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.110 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.060 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.040 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.030 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.030 | Inavolisib | — uncovered |
| HYPOXIA | 0.010 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.010 | Inavolisib | — uncovered |